216
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

, , &
Pages 722-725 | Received 29 Feb 2016, Accepted 24 Jun 2016, Published online: 23 Sep 2016
 

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.1080/10428194.2016.1207764.

Funding

This study was sponsored in part by Celgene, and by the MD Anderson Cancer Center Support Grant CA016672 (PI: Dr. Ronald DePinho) and Award Number P01 CA049639 (PI: Dr. Richard Champlin) from the National Cancer Institute.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.